Land: Malta
Språk: engelsk
Kilde: Medicines Authority
LATANOPROST
Viatris Hellas Ltd 253-255, Mesogion Avenue, 154 51 Neo Psychiko, Athens,, Greece
S01EE01
LATANOPROST 50 µg/ml
EYE DROPS, SOLUTION
LATANOPROST 50 µg/ml
POM
OPHTHALMOLOGICALS
Authorised
2005-10-31
Page 1 of 7 PACKAGE LEAFLET: INFORMATION FOR THE USER XALATAN 50 MICROGRAMS/ML EYE DROPS, SOLUTION Latanoprost READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or the doctor treating your child or pharmacist. • This medicine has been prescribed for you or for your child only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or the doctor treating your child or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Xalatan is and what it is used for 2. What you need to know before you use Xalatan 3. How to use Xalatan 4. Possible side effects 5. How to store Xalatan 6. Contents of the pack and other information 1. WHAT XALATAN IS AND WHAT IT IS USED FOR Xalatan belongs to a group of medicines known as prostaglandin analogues. It works by increasing the natural outflow of fluid from inside the eye into the bloodstream. Xalatan is used to treat conditions known as OPEN ANGLE GLAUCOMA and OCULAR HYPERTENSION in adults. Both of these conditions are linked with an increase in the pressure within your eye, eventually affecting your eye sight. Xalatan is also used to treat increased eye pressure and glaucoma in all ages of children and babies. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE XALATAN Xalatan can be used in adult men and women (including the elderly) and in children from birth to 18 years of age. Xalatan has not been investigated in prematurely born infants (less than 36 weeks gestation). Page 2 of 7 DO NOT USE XALATAN: • If you are allergic (hypersensitive) to latanoprost or any of the other ingredients of this medicine (listed in section 6) WARNINGS AND PRECAUTIONS Talk to your doctor or the doctor treating your child or pharmacist before using Xalatan Les hele dokumentet
Page 1 of 11 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT _ _ Xalatan 50 micrograms/mL Eye drops, solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 mL Eye drops solution contains 50 micrograms of latanoprost. One drop contains approximately 1.5 micrograms latanoprost. Excipient with known effect Benzalkonium chloride 0.2 mg/mL is included as a preservative. Sodium dihydrogen phosphate monohydrate (E339i) 7.70 mg/mL. Disodium phosphate anhydrous (E339ii) 1.55 mg/mL. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Eye drops, solution. The solution is a clear, colourless liquid. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma and ocular hypertension in adults (including the elderly). Reduction of elevated IOP in paediatric patients with elevated IOP and paediatric glaucoma. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _ _ _Adults (including the elderly) _ Recommended therapy is one eye drop in the affected eye(s) once daily. Optimal effect is obtained if Xalatan is administered in the evening. The dosage of Xalatan should not exceed once daily since it has been shown that more frequent administration decreases the IOP lowering effect. If one dose is missed, treatment should continue with the next dose as normal. _Paediatric population _ Xalatan Eye drops, solution may be used in paediatric patients at the same posology as in adults. No data are available for preterm infants (less than 36 weeks gestational age). Data in the age group < 1 year (4 patients) are limited (see section 5.1). Page 2 of 11 Method of administration As with any eye drops, to reduce possible systemic absorption, it is recommended that the lachrymal sac be compressed at the medial canthus (punctal occlusion) for one minute. This should be performed immediately following the instillation of each drop. Contact lenses should be removed before instillation of the eye drops and may be reinserted after 15 Les hele dokumentet